← Leaderboards
Hongjie Guo
Antiger Therapeutics Inc.
$581,569
Attributed
$869,457
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $303.3K · FY2023–25$500K$375K$250K$125K$0
'23
'24
'25
Funding mix
By agency
NIH$869,457 · 3
By mechanism
R43$869,457 · 3
Top collaborators
- Chang Liu2 shared
Others in their field
Other Rising Stars on “Immunity”
- Angee Greer · Ppd Development Lp$82,531,927
- Rhea Coler · Seattle Children'S Hospital$35,184,139
- Christina Millin · Rho Federal Systems Division, Inc.$31,828,916
- Cathie Snyder · Rho Federal Systems Division, Inc.$13,500,724
- Jason Dickens · Duke University$12,259,409
- Suma Babu · Massachusetts General Hospital$11,004,714
Research focus
ImmunityInnovationEngineeringHybridomasImmunosuppressionInfection ControlComplexDisulfide BondCommercial ApplicationHla AntigensDimerizationImmunogenicityAntibodiesImmunotherapyAutomobile DrivingCellsCell Culture SystemBiochemicalBiologicalBiological ProductsChimeric ProteinsFda ApprovedAntigensIn Vitro
Grant awards (3)
Peptide-HLA-DQ8 biologics for antigen-specific therapy in Type 1 Diabetes$303,274
R43 · FY2025 · AI · contact PI
Peptide-HLA-DQ2 biologics for antigen-specific therapy in Celiac Disease$293,680
R43 · FY2024 · AI · contact PI
Class II Human Leukocyte Antigen biologics for antibody-mediated graft rejection.$272,503
R43 · FY2023 · AI · contact PI